Mylan has reported lower than expected full year earnings and 2019 forecasts, thanks partly to delays in its generic Advair approval and continuing problems at its US manufacturing plant.
Pfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to claims for hundreds of millions of pounds from the NHS.
Mylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price competitor approved ahead of patent expiry on AbbVie’s inflammatory diseas
Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.